Epicentre Technologies Corporation
5602 Research Park Blvd Ste 200, Madison, WI, 53719, United States
Overview
Epicentre, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for RNA amplification and gene expression analysis, transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research and purification. In addition to our broad molecular biology product line, Epicentre also offers custom protein manufacturing.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Bioinformatics
- Biotechnology
- Clinical Trials
- Genetics
- Life Science
- Manufacturing
Investment portfolio
- Alethia BioTherapeutics
Participated · Series A · Sep 2010
Alethia Biotherapeutics is a biotechnology company based in Montréal, Québec, focused on developing therapeutic monoclonal antibodies. Founded in 2002, the company uses its patented STAR discovery technology to identify novel, clinically relevant targets and has built a pipeline that includes Siglec-15, a regulator of osteoclast differentiation and function. Management is led by Yves Cornellier (President & CEO) and Dr. Mario Filion (CSO). Its lead bone antiresorptive candidate is AB-25E9. The company plans to use proceeds from its recent financing to advance AB-25E9 into the studies required to submit an IND. The financing was reported at $4.7M to support those development activities. Alethia Biotherapeutics is focused on discovering tissue-specific disease targets and developing monoclonal antibodies as focused therapeutics. The company uses a discovery and validation platform to identify novel disease-specific targets. Its most advanced program targets the secreted factor clusterin, implicated in tumor progression; the lead antibody enhanced chemotherapeutic response and inhibited metastatic invasion in animal studies. In ovarian cancer Alethia is developing an antibody against KAAG-1, which is over‑expressed in more than 90% of ovarian tumors. Alethia closed a C$9.6m financing and will use the new capital to advance its lead pre-clinical programs into clinical development over the next 18 months.
Team
No current team members are available.